Detail akcie Novavax Rg online

Business Summary: Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Novavax Inc revenues increased 65% to $1.12B. Net income totaled $440.3M vs. loss of $187.5M. Revenues reflect Product Sales increase from $190.2M to $685M. Net Income reflects General and administrative - Balancing decrease of 57% to $129.8M (expense), Research and development - Balancing decrease of 12% to $322.8M (expense), Labor & Related Expenses in R&D decrease of 33% to $14.1M (expense).